Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012–2017

摘要

PurposePre-exposure prophylaxis (PrEP) with oral emtricitibine/tenofovir disoproxil fumarate (TDF/FTC) reduces the risk of HIV infection by >90% when taken as prescribed. Trends in prevalence of PrEP use, which account for persons who have stopped PrEP, increased through 2016, but have not been described since. MethodsAnnual prevalence estimates of unique, TDF/FTC PrEP users (individuals with ≥1?day of a filled PrEP prescription in a given year) in the United States (US) were generated for 2012–2017 from a national prescription database. A validated algorithm was used to distinguish users of TDF/FTC for HIV or chronic Hepatitis B treatment or postexposure prophylaxis from PrEP users. We calculated annual prevalence of PrEP use overall and by age, sex, and region. We used log-transformation to calculate estimated annual percent change (EAPC) in the prevalence of PrEP use. ResultsAnnual prevalence of PrEP use increased from 3.3/100,000 population in 2012 to 36.7 in 2017 –a 56% annual increase from 2012 to 2017 (EAPC:?+56%). Annual prevalence of PrEP use increased faster among men than among women (EAPC:?+68% and?+5%, respectively). By age group, annual prevalence of PrEP use increased fastest among 25- to 34-year olds (EAPC:?+61%) and slowest among ≥55-year olds (EAPC:?+52%) and ≤24-year olds (EAPC:?+51%). In 2017, PrEP use was lowest in the South (29.8/100,000) and highest in the Northeast (62.3/100,000). ConclusionsDespite overall increases in the annual number of TDF/FTC PrEP users in the US from 2012 to 2017, the growth of PrEP coverage is inconsistent across groups. Efforts to optimize PrEP access are especially needed for women and for those living in the South.